Segui
Anne Searls De Groot
Anne Searls De Groot
Altri nomiAnne S. DeGroot, Anne DeGroot, Annie De Groot
EpiVax, Inc and (formerly) Center for Vaccines and Immunology, UGA
Email verificata su epivax.com - Home page
Titolo
Citata da
Citata da
Anno
Immunogenicity of protein therapeutics
AS De Groot, DW Scott
Trends in immunology 28 (11), 482-490, 2007
6222007
Activation of natural regulatory T cells by IgG Fc–derived peptide “Tregitopes”
AS De Groot, L Moise, JA McMurry, E Wambre, L Van Overtvelt, ...
Blood, The Journal of the American Society of Hematology 112 (8), 3303-3311, 2008
4492008
T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation
V Jawa, LP Cousens, M Awwad, E Wakshull, H Kropshofer, AS De Groot
Clinical immunology 149 (3), 534-555, 2013
2672013
Immuno‐informatics: Mining genomes for vaccine components
AS De Groot, H Sbai, CS Aubin, J McMurry, W Martin
Immunology and cell biology 80 (3), 255-269, 2002
2552002
From genome to vaccine: in silico predictions, ex vivo verification
AS De Groot, A Bosma, N Chinai, J Frost, BM Jesdale, MA Gonzalez, ...
Vaccine 19 (31), 4385-4395, 2001
2502001
Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics
AS De Groot, W Martin
Clinical immunology 131 (2), 189-201, 2009
2382009
Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences
GE Meister, CGP Roberts, JA Berzofsky, AS De Groot
Vaccine 13 (6), 581-591, 1995
2151995
Immunomics: discovering new targets for vaccines and therapeutics
AS De Groot
Drug discovery today 11 (5-6), 203-209, 2006
1992006
Emerging vaccine informatics
Y He, R Rappuoli, AS De Groot, RT Chen
BioMed Research International 2010, 2010
1832010
Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein
E Koren, AS De Groot, V Jawa, KD Beck, T Boone, D Rivera, L Li, ...
Clinical Immunology 124 (1), 26-32, 2007
1682007
Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix
JRA Schafer, BM Jesdale, JA George, NM Kouttab, AS De Groot
Vaccine 16 (19), 1880-1884, 1998
1521998
Tregitope update: mechanism of action parallels IVIg
LP Cousens, R Tassone, BD Mazer, V Ramachandiran, DW Scott, ...
Autoimmunity Reviews 12 (3), 436-443, 2013
1422013
From genome to vaccine—new immunoinformatics tools for vaccine design
AS De Groot, JA Berzofsky
Methods 4 (34), 425-428, 2004
1402004
An interactive Web site providing major histocompatibility ligand predictions: application to HIV research
AS De Groot, BM JESDALE, E SZU, JR SCHAFER, RM CHICZ, ...
AIDS research and human retroviruses 13 (7), 529-531, 1997
1401997
Prediction of immunogenicity for therapeutic proteins: state of the art
AS De Groot, L Moise
Current Opinion in Drug Discovery and Development 10 (3), 332, 2007
1362007
Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates
AS De Groot, J McMurry, L Moise
Current opinion in pharmacology 8 (5), 620-626, 2008
1322008
In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity
LP Cousens, N Najafian, F Mingozzi, W Elyaman, B Mazer, L Moise, ...
Journal of clinical immunology 33, 43-49, 2013
1312013
Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008–2009 conventional influenza vaccine
AS De Groot, M Ardito, EM McClaine, L Moise, WD Martin
Vaccine 27 (42), 5740-5747, 2009
1282009
Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach
AS De Groot, B Jesdale, W Martin, C Saint Aubin, H Sbai, A Bosma, ...
Vaccine 21 (27-30), 4486-4504, 2003
1182003
T cell epitope: friend or foe? Immunogenicity of biologics in context
CA Weber, PJ Mehta, M Ardito, L Moise, B Martin, AS De Groot
Advanced drug delivery reviews 61 (11), 965-976, 2009
1142009
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20